靶向OXCT1介导的酮体代谢重编程巨噬细胞通过CD8+ T细胞促进肝细胞癌抗肿瘤免疫
本研究探讨3-氧代酸辅酶A转移酶1(OXCT1)在肝细胞癌(HCC)中对肿瘤相关巨噬细胞(TAMs)的调控作用。通过人HCC标本多重免疫组化及巨噬细胞条件性敲除OXCT1小鼠模型,发现OXCT1在TAMs中高表达,其缺陷可重编程TAMs为抗肿瘤表型,减少CD8+ T细胞耗竭并增强细胞毒性。机制上,OXCT1通过琥珀酸-H3K4me3-Arg1轴促进Arg1转录;匹莫齐特抑制OXCT1可模拟该效应。OXCT1高表达与患者不良生存正相关。
要点
- OXCT1在HCC的TAMs中高表达,且与患者不良生存正相关。
- 巨噬细胞OXCT1缺陷通过琥珀酸-H3K4me3-Arg1轴减少CD8+ T细胞耗竭并抑制肿瘤生长。
- OXCT1抑制剂匹莫齐特可抑制Arg1表达和促肿瘤极化,减缓肿瘤生长。
核心结论
- OXCT1在表观遗传层面抑制抗肿瘤免疫,抑制TAMs中OXCT1活性可能是治疗肝癌的有效途径。
研究设计与样本
- 对人HCC标本进行多重免疫组化实验以探究OXCT1表达模式。
- 构建LysMcreOXCT1f/f小鼠(巨噬细胞条件性敲除OXCT1)以探究OXCT1在小鼠HCC TAMs中的作用。
主要发现
- OXCT1在稳态肝脏巨噬细胞中高表达,且在TAMs中表达进一步增加。
- 巨噬细胞OXCT1缺陷通过将TAMs重编程为抗肿瘤表型、减少CD8+ T细胞耗竭并增加其细胞毒性来抑制肿瘤生长。
- 高OXCT1表达诱导TAMs中酮解副产物琥珀酸积累,通过增加Arg1启动子H3K4me3水平促进Arg1转录。
- 匹莫齐特抑制OXCT1可抑制Arg1表达及TAM向促肿瘤表型极化,减少CD8+ T细胞耗竭并减缓肿瘤生长。
- 巨噬细胞中OXCT1高表达与HCC患者不良生存正相关。
临床怎么用
- 作者认为抑制TAMs中OXCT1活性可能是治疗肝癌的有效方法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The liver is the main organ of ketogenesis, while ketones are mainly metabolized in peripheral tissues via the critical enzyme 3-oxoacid CoA-transferase 1 (OXCT1). We previously found that ketolysis is reactivated in hepatocellular carcinoma (HCC) cells through OXCT1 expression to promote tumor progression; however, whether OXCT1 regulates antitumor immunity remains unclear. METHODS: To investigate the expression pattern of OXCT1 in HCC in vivo, we conducted multiplex immunohistochemistry experiments on human HCC specimens. To explore the role of OXCT1 in mouse HCC tumor-associated macrophages (TAMs), we generated LysMcreOXCT1f/f (OXCT1 conditional knockout in macrophages) mice. RESULTS: Here, we found that inhibiting OXCT1 expression in tumor-associated macrophages reduced CD8+ T-cell exhaustion through the succinate-H3K4me3-Arg1 axis. Initially, we found that OXCT1 was highly expressed in liver macrophages under steady state and that OXCT expression was further increased in TAMs. OXCT1 deficiency in macrophages suppressed tumor growth by reprogramming TAMs toward an antitumor phenotype, reducing CD8+ T-cell exhaustion and increasing CD8+ T-cell cytotoxicity. Mechanistically, high OXCT1 expression induced the accumulation of succinate, a byproduct of ketolysis, in TAMs, which promoted Arg1 transcription by increasing the H3K4me3 level in the Arg1 promoter. In addition, pimozide, an inhibitor of OXCT1, suppressed Arg1 expression as well as TAM polarization toward the protumor phenotype, leading to decreased CD8+ T-cell exhaustion and slower tumor growth. Finally, high expression of OXCT1 in macrophages was positively associated with poor survival in patients with HCC. CONCLUSIONS: In conclusion, our results demonstrate that OXCT1 epigenetically suppresses antitumor immunity, suggesting that suppressing OXCT1 activity in TAMs could be an effective approach for treating liver cancer. IMPACT AND IMPLICATIONS: The intricate metabolism of liver macrophages plays a critical role in shaping hepatocellular carcinoma progression and immune modulation. Targeting macrophage metabolism to counteract immune suppression presents a promising avenue for hepatocellular carcinoma treatment. Herein, we found that the ketogenesis gene OXCT1 was highly expressed in tumor-associated macrophages (TAMs) and promoted tumor growth by reprogramming TAMs toward a protumor phenotype. Pharmacological targeting or genetic downregulation of OXCT1 in TAMs enhances antitumor immunity and slows tumor growth. Our results suggest that suppressing OXCT1 activity in TAMs could be an effective approach for treating liver cancer.
引用
- Zhu CX, Yan K, Chen L, et al. Targeting OXCT1-mediated ketone metabolism reprograms macrophages to promote antitumor immunity via CD8+ T cells in hepatocellular carcinoma. J Hepatol. 2024. PMID: 38759889. doi:10.1016/j.jhep.2024.05.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。